Rhenman & Partners Asset Management AB grew its stake in Mirati Therapeutics, Inc. (NASDAQ:MRTX – Free Report) by 25.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 175,000 shares of the biotechnology company’s stock after purchasing an additional 35,000 shares during […]